
#### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

### (19) World Intellectual Property Organization

International Bureau





(10) International Publication Number WO 2012/054870 A3

- (51) International Patent Classification: *G01N 33/576* (2006.01)
- (21) International Application Number:

PCT/US2011/057347

(22) International Filing Date:

21 October 2011 (21.10.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/405,619 21 October 2010 (21.10.2010)

US

- (71) Applicant (for all designated States except US): VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 130 Waverly Street, Cambridge, MA 02139 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): FLEMING, Mark, Andrew [US/US]; 3 Ivy Circle, Winchester, MA 01890 (US). HARE, Brian, J. [US/US]; 34 Hamilton Road #502, Arlington, MA 02474 (US).
- (74) Agents: KISSLING, Heather R. et al.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,


CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- (88) Date of publication of the international search report: 10 January 2013

#### (54) Title: BIOMARKERS FOR HCV INFECTED PATIENTS



(57) Abstract: The invention relates to biomarkers measurable in a human subject that have prognostic value with respect to efficacy of therapeutic treatments for Hepatitis C viral infection. The markers also are believed to have value for diagnosis liver health/liver damage.





International application No PCT/US2011/057347

A. CLASSIFICATION OF SUBJECT MATTER INV. G01N33/576

ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

#### **B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols) G01N

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

EPO-Internal, WPI Data, Sequence Search

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Α	US 2010/040577 A1 (ALBERT MATTHEW [FR] ET AL) 18 February 2010 (2010-02-18) whole doc, in particular claims 9-12, [0010], [0011], [0076]	1-47
Α	MASAHIKO KODA ET AL: "Fibroindex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C", HEPATOLOGY, vol. 45, no. 2, 1 February 2007 (2007-02-01), pages 297-306, XP55020655, ISSN: 0270-9139, DOI: 10.1002/hep.21520 whole doc, in particular p. 305, left col.	1,3-8, 12-30, 32,35, 37,38, 40,41, 43-46

	Х	Further documents are listed in the continuation of Box C.	
7	Sne	cial sategories of cited documents :	

Χ See patent family annex.

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other
- document published prior to the international filing date but later than the priority date claimed
- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search Date of mailing of the international search report 12 November 2012 19/11/2012 Authorized officer Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016 Lüdemann, Susanna

International application No
PCT/US2011/057347

gamma-inducible protein 10 - A predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients", JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, LIPPINCOTT WILLIAMS AND WILKINS,PHILADELPHIA, PA, US, vol. 45, no. 3, 1 July 2007 (2007-07-01), pages 262-268, XP009157012, ISSN: 1525-4135, DOI: 10.1097/QAI.0B013E3180559219 whole doc, in particular title, abstract and fig.2  X T. POYNARD ET AL: "Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial", JOURNAL OF VIRAL HEPATITIS, vol. 9, no. 2, 1 March 2002 (2002-03-01), pages 128-133, XP55020656, ISSN: 1352-0504, DOI: 10.1046/j.1365-2893.2002.00341.x whole doc, in particular p. 128, right col p. 129, left col, first paragraph; p. 129 (left col. 2nd paragraph and table 1)  X US 2004/110938 A1 (PAREKH RAJESH BHIKHU [GB] ET AL) 10 June 2004 (2004-06-10) 38 Whole doc, in particular seq. id. no. 674	3-8, -30, ,35, ,38, ,41,
A ZEREMSKI MARIJA ET AL: "Interferon gamma-inducible protein 10 - A predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected 37 patients", 40 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY 43 SYNDROMES, LIPPINCOTT WILLIAMS AND WILKINS, PHILADELPHIA, PA, US, vol. 45, no. 3, 1 July 2007 (2007-07-01), pages 262-268, XP009157012, ISSN: 1525-4135, DOI: 10.1097/QAI.OB013E3180559219 whole doc, in particular title, abstract and fig.2  X T. POYNARD ET AL: "Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial", 37 JOURNAL OF VIRAL HEPATITIS, 40 vol. 9, no. 2, 1 March 2002 (2002-03-01), pages 128-133, XP55020656, ISSN: 1352-0504, DOI: 10.1046/j.1365-2893.2002.00341.x whole doc, in particular p. 128, right col p. 129, left col, first paragraph; p. 129 (left col. 2nd paragraph and table 1)  X US 2004/110938 A1 (PAREKH RAJESH BHIKHU 32 [GB] ET AL) 10 June 2004 (2004-06-10) 38 whole doc, in particular seq. id. no. 674	3-8, -30, ,35, ,38,
liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial", JOURNAL OF VIRAL HEPATITIS, vol. 9, no. 2, 1 March 2002 (2002-03-01), pages 128-133, XP55020656, ISSN: 1352-0504, DOI: 10.1046/j.1365-2893.2002.00341.x whole doc, in particular p. 128, right col p. 129, left col, first paragraph; p. 129 (left col. 2nd paragraph and table 1)  X US 2004/110938 A1 (PAREKH RAJESH BHIKHU [GB] ET AL) 10 June 2004 (2004-06-10) whole doc, in particular seq. id. no. 674	
[GB] ET AL) 10 June 2004 (2004-06-10)  A whole doc, in particular seq. id. no. 674  1-2	3-8, -30, ,35, ,38, ,41, -46
A   whole doc, in particular seq. id. no. 674   1-2	,33 <b>,</b> -40
and [0090] 36	29,35, ,45-47
NAT HEALTH RESEARCH INSTITUTES [TW]) 33 25 July 2007 (2007-07-25) 36	-40,
abstract, table 2, p. 21, [0004],[0046]	
RAMESH [US]; ALSOBROOK JOHN P ĪI) 38- 11 July 2002 (2002-07-11)	,33, -40
A whole doc, in particular p. 110-120,	29,35, ,45-47
X US 2007/099242 A1 (HEINECKE JAY W [US] ET 32 AL) 3 May 2007 (2007-05-03) 38	,33, -40
A whole document, in particular claims 32 1-2	29,35, ,45-47
-/	,
	, , , ,

8

International application No
PCT/US2011/057347

,	tion). DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2010/105620 A1 (BOWDISH KATHERINE S [US] ET AL) 29 April 2010 (2010-04-29) whole doc, in particular seq. id. no. 127,	1-29,32, 33,35, 36, 38-40, 45-47
	fig. 5, [0013], [0061], [0062], [0074], fig.5	
X	WO 2009/127693 A1 (INST NAT SANTE RECH MED [FR]; LOTTEAU VINCENT [FR]) 22 October 2009 (2009-10-22)	1-29,32, 33,35, 38-40, 45-47
	whole doc, in particular claim 6 and 9, p. 13, line 33, p. 69, line 28	
X	WO 2010/106140 A1 (UNIV ANGERS [FR]; CT HOSPITALIER UNIVERSITAIRE D [FR]; CALES PAUL [FR]) 23 September 2010 (2010-09-23)	1-29,32, 33,35, 36, 38-40, 45-47
	whole doc, in particular p. 2, lines 19-22, p. 15, lines 24-32 and claim 6	
X	WO 2008/031051 A2 (UNITED THERAPEUTICS CORP [US]; GANGADHARAN BEVIN [GB]; ZITZMANN NICOLE) 13 March 2008 (2008-03-13)	1-29,32, 33,35, 36, 38-40, 45-47
	whole doc, in particular [0005],[0007],[0011],[0019],[0031] fig.1 and 5, claim 3, 8 and 16	
X	WO 2009/034055 A1 (NOVARTIS FORSCHUNGSSTIFTUNG [CH]; UNIV HOSPITAL BASEL [CH]; CHRISTEN V) 19 March 2009 (2009-03-19)	1-29,32, 33,35, 36, 38-40, 45-47
	whole doc, in particular title, introduction, p. 34, claims 1, 6, 18-20.	
Х	US 2009/117591 A1 (CORRALES IZQUIERDO FERNANDO [ES] ET AL) 7 May 2009 (2009-05-07)	1-29,32, 33,35, 36, 38-40, 45-47
	whole doc, in particular [0022], [0004], claims 1,9 and example on p. 4	
X A	US 6 271 362 B1 (MORIKAWA MINORU [JP] ET AL) 7 August 2001 (2001-08-07) the whole document	32,33, 38-40 1-29,35, 36,45-47

8

International application No. PCT/US2011/057347

# **INTERNATIONAL SEARCH REPORT**

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Claims Nos.:  because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. X As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
1, 3-8, 12-30, 32, 35, 37, 40, 41, 43-46(all partially)
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.  The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.  No protest accompanied the payment of additional search fees.

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1, 3-8, 12-30, 32, 35, 37, 38, 40, 41, 43-46(all partially)

A method for evaluating a human subject infected with hepatitis C virus (HCV) for a treatment, the method comprising a) obtaining the measurement of the biomarker LPA and b) evaluating the subject for HCV treatment from the output of a model, wherein the inputs to said model comprise said measurement of the at least one biomarker; furthermore methods of treating HCV infection, a kit, computer-readabel medium, a medical diagniostic test system, a method of developing a model, use of at least one antibody, all based on LPA as marker.

2-34. claims: 1-47(partially)

A method for evaluating a human subject infected with hepatitis C virus (HCV) for a treatment, the method comprising a) obtaining the measurement of a biomarker and b) evaluating the subject for HCV treatment from the output of a model, wherein the inputs to said model comprise said measurement of the at least one biomarker; furthermore methods of treating HCV infection, a kit, computer-readabel medium, a medical diagniostic test system, a method of developing a model, use of at least one antibody, wherein the marker is CDNP1, ... FCGBP (list of markers according to list of claim 1).

35-39. claims: 2-9, 12-29, 31, 33, 34, 36, 37, 39, 40, 42-45, 47(all partially)

A method for evaluating a human subject infected with hepatitis C virus (HCV) for a treatment, the method comprising a) obtaining the measurement of a biomarker and b) evaluating the subject for HCV treatment from the output of a model, wherein the inputs to said model comprise said measurement of the at least one biomarker; furthermore methods of treating HCV infection, a kit, computer-readabel medium, a medical diagniostic test system, a method of developing a model, use of at least one antibody, all based on either PZP, APOC4, CLEC3B, APOB or CD5L as marker (list of markers according to list of claim 2).

---

Information on patent family members

International application No
PCT/US2011/057347

	ent document n search report		Publication date		Patent family member(s)		Publication date
US 2	2010040577	A1	18-02-2010	US US	2010040577 2012171158		18-02-2010 05-07-2012
US 2	2004110938	A1	10-06-2004	NONE			
EP :	1811041	A1	25-07-2007	EP JP JP SG US	1811041 4297942 2007252366 134283 2007184476	B2 A A1	25-07-2007 15-07-2009 04-10-2007 29-08-2007 09-08-2007
WO (	02053742	A2	11-07-2002	CA EP JP WO	2433782 1383893 2005509400 02053742	A2 A	11-07-2002 28-01-2004 14-04-2005 11-07-2002
US 2	2007099242	A1	03-05-2007	US US	2007099242 2011212477		03-05-2007 01-09-2011
US 7	2010105620	A1	29-04-2010	AU CA CN EP JP US US	2009303304 2739663 102317314 2379585 2012504969 2010105620 2012135938 2010042890	A1 A2 A A1 A1	15-04-2010 15-05-2010 11-01-2012 26-10-2011 01-03-2012 29-04-2010 31-05-2012 15-04-2010
WO a	2009127693	A1	22-10-2009	EP JP US WO WO	2269074 2011517779 2011091994 2009127693 2009127913	A A1 A1	05-01-2011 16-06-2011 21-04-2011 22-10-2009 22-10-2009
WO 2	2010106140	A1	23-09-2010	CN EP JP US WO	102439456 2409154 2012520995 2012010824 2010106140	A1 A A1	02-05-2012 25-01-2012 10-09-2012 12-01-2012 23-09-2010
WO 2	2008031051	A2	13-03-2008	EP EP EP US WO	2067043 2469282 2469283 2008085526 2008031051	A1 A1 A1	10-06-2009 27-06-2012 27-06-2012 10-04-2008 13-03-2008
wo :	2009034055	A1	19-03-2009	CN EP US WO	101821629 2191274 2010167302 2009034055	A1 A1	01-09-2010 02-06-2010 01-07-2010 19-03-2009
US 7	2009117591	A1	07-05-2009	AU BR CA CN EP ES JP	2006264946 PI0613169 2613833 101356439 1918715 2288358 2009500597	A2 A1 A A1 A1	11-01-2007 21-12-2010 11-01-2007 28-01-2009 07-05-2008 01-01-2008 08-01-2009

Information on patent family members

International application No
PCT/US2011/057347

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
		US WO	2009117591 A1 2007003670 A1	07-05-2009 11-01-2007
US 6271362 B1	07-08-2001	AT AU DE EP JP JP US WO	315644 T 2085195 A 69534743 T2 0776972 A1 3619282 B2 8112096 A 6271362 B1 9527057 A1	15-02-2006 23-10-1995 02-11-2006 04-06-1997 09-02-2005 07-05-1996 07-08-2001 12-10-1995